Back to results
US 2020/0268908 A1Published application
Rabies vaccine
AssigneeCureVac AG
InventorsMargit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeCureVac AG
InventorsMargit SCHNEE, Thomas KRAMPS, Lothar STITZ, Benjamin PETSCH
Estimating the term…
The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.
mRNA sequence comprising a coding region, encoding at least one antigenic peptide or protein derived from the glycoprotein G (RAV-G), nucleoprotein N (RAV-N), phospoprotein P (RAV-P), matrix protein M (RAV-M) or RNA polymerase L (RAV-L) of Rabies virus or a fragment, variant or derivative thereof;
Dependencies are inferred from the claim text.